Name: Viczján Gábor
Degree
- PhD, Debreceni Egyetem (2023)
Publication list
2023
2022
Óvári, I.,
Szilágyi, V.,
Viczján, G.,
Lampé, N.,
Bege, M.,
Borbás, A.,
Herczeg, P.,
Juhász, B.,
Gesztelyi, R.,
Erdei, T.:
Egy újonnan szintetizált adenozin analóg, a hipoxantin-triciklánó hatása izolált patkány bal és jobb pitvaron.
Eü. Innov. Szle. 1 (1), 9-16, 2022.
Viczján, G.,
Szilágyi, A.,
Takács, B.,
Óvári, I.,
Szekeres, R.,
Tarjányi, V.,
Erdei, T.,
Teleki, V.,
Zsuga, J.,
Szilvássy, Z.,
Juhász, B.,
Varga, B.,
Gesztelyi, R.:
The effect of a long-term treatment with cannabidiol-rich hemp extract oil on the adenosinergic system of the Zucker Diabetic Fatty (ZDF) rat atrium.
Front. Pharmacol. 13 1-12, 2022.
Journal metrics:
Q1 Pharmacology
Q1 Pharmacology (medical)
2021
Viczján, G.,
Erdei, T.,
Óvári, I.,
Lampé, N.,
Szekeres, R.,
Bombicz, M.,
Takács, B.,
Szilágyi, A.,
Zsuga, J.,
Szilvássy, Z.,
Juhász, B.,
Gesztelyi, R.:
A Body of Circumstantial Evidence for the Irreversible Ectonucleotidase Inhibitory Action of FSCPX, an Agent Known as a Selective Irreversible A1 Adenosine Receptor Antagonist So Far.
Int. J. Mol. Sci. 22 (18), 1-21, 2021.
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
Q1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
Q1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
D1 Spectroscopy
2019
Szabó, A.,
Viczján, G.,
Erdei, T.,
Simon, I.,
Kiss, R.,
Szentmiklósi, J.,
Juhász, B.,
Papp, C.,
Zsuga, J.,
Pintér, Á.,
Szilvássy, Z.,
Gesztelyi, R.:
Accuracy and Precision of the Receptorial Responsiveness Method (RRM) in the Quantification of A1 Adenosine Receptor Agonists.
Int. J. Mol. Sci. 20 (24), 1-14, 2019.
Journal metrics:
Q2 Catalysis
Q1 Computer Science Applications
Q1 Inorganic Chemistry
Q1 Medicine (miscellaneous)
Q2 Molecular Biology
Q1 Organic Chemistry
Q1 Physical and Theoretical Chemistry
Q1 Spectroscopy
Szabó, A.,
Erdei, T.,
Viczján, G.,
Kiss, R.,
Zsuga, J.,
Papp, C.,
Pintér, Á.,
Juhász, B.,
Szilvássy, Z.,
Gesztelyi, R.:
An Advanced in silico Modelling of the Interaction between FSCPX, an Irreversible A1 Adenosine Receptor Antagonist, and NBTI, a Nucleoside Transport Inhibitor, in the Guinea Pig Atrium.
Molecules. 24 (12), 1-16, 2019.
Journal metrics:
Q2 Analytical Chemistry
Q2 Chemistry (miscellaneous)
Q2 Drug Discovery
Q2 Medicine (miscellaneous)
Q3 Molecular Medicine
Q2 Organic Chemistry
Q1 Pharmaceutical Science
Q2 Physical and Theoretical Chemistry
updated: 2024-04-21, 01:36
